Search filters

Novartis acquires option to acquire Zurich-based startup Cellerys

Novartis has signed a collaboration agreement and an option to acquire Cellerys. The Zurich-based startup is researching an innovative therapy to combat multiple sclerosis (MS).

Dermavant raises USD 200m Financing

Dermavant Sciences announced that the company has entered into a USD 160m revenue interest purchase and sale agreement for its investigational product tapinarof with three participants.

Swiss Nuclides raises CHF 2.6m in Series A Financing

Swiss Nuclides AG, a developer of novel radionuclide PET tracers for the precision diagnostics, has raised CHF 2.6m.

UMB Solutions acquires ubitec

ubitec AG, a developer of innovative software solutions for digitization, was acquired by UMB Solutions AG, a leading Swiss IT services provider.

DomoSafety SA closes a Serie B financing round

DomoSafety SA, a leading company in the digital health segment, announced the successful closing of its Series B financing round.

Faveeo SA closes a Series B financing round

Faveeo SA, a Swiss start-up, announced the successful closing of its Series B financing round.

Haya Therapeutics completes CHF 18m Seed Financing Round

HAYA Therapeutics SA announced the successful closing of its CHF 18m seed round.

Oculis closes an oversubscribed USD 57m Series C financing round

Oculis S.A., a late-stage biopharmaceutical company, focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, has closed an oversubscribed USD 57m Series C financing round.

RELIEF THERAPEUTICS Holding SA to acquire Applied Pharma Research S.A.

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company, acquires Applied Pharma Research S.A., a privately held Swiss pharmaceutical company.

Sale of Mestex AG to Grünenthal

The previous owners of Mestex AG, a Swiss biotech company developing, sold their shares and stock options to the pharmaceutical company Grünenthal

You are currently offline. Some pages or content may fail to load.